Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004669 | 0.88 | CYP11B2 (0.47) | CYP11B2CYP11B1PRMT5WDR77 | |
| SCHEMBL18004639 | 0.84 | CYP11B2 (0.40) | CYP11B2CYP11B1PRMT5WDR77 | |
| SCHEMBL18006079 | 0.84 | ERBB2 (0.47) | CYP11B2CYP11B1ERBB2 | |
| SCHEMBL18006164 | 0.83 | CYP11B1 (0.48) | CYP11B2CYP11B1PRMT5WDR77ERBB2 | |
| SCHEMBL18004678 | 0.83 | CYP11B2 (0.52) | CYP11B2CYP11B1PRMT5WDR77CHRNB4 | |
| SCHEMBL17969086 | 0.82 | ERBB2 (0.49) | CYP11B2CYP11B1ERBB2 | |
| SCHEMBL18006086 | 0.82 | TAAR1 (0.44) | CYP11B2CYP11B1 | |
| SCHEMBL18005622 | 0.82 | CYP11B1 (0.40) | CYP11B2CYP11B1PRMT5WDR77 | |
| SCHEMBL18006135 | 0.81 | XDH (0.42) | CYP11B2 | |
| SCHEMBL18006081 | 0.78 | CYP11B1 (0.40) | CYP11B2CYP11B1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CYP11B2 227/4885CYP11B1 126/4885PRMT5 917/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | CYP11B2 227/4885CYP11B1 126/4885PRMT5 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.